Thoracic paravertebral block with different doses of liposomal bupivacaine versus ropivacaine for postoperative analgesia in single-port thoracoscopic lung surgery: a randomized clinical trial.
Liyuan Ren, Zhenhua Nan, Yanshuang Li et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized clinical trial evaluated the analgesic efficacy of thoracic paravertebral block (TPVB) using different doses of liposomal bupivacaine (LB) compared to ropivacaine in 105 patients undergoing single-port thoracoscopic lung surgery. The study found that high-dose LB resulted in a lower area under the curve for pain at activity compared to low-dose LB (p = 0.0071), but not compared to ropivacaine.
Key findings
- AUC-aNRS was significantly lower in the high-dose LB group compared to the low-dose LB group (p = 0.0071).
- Cumulative opioid consumption was lower in the high-dose LB group compared to the low-dose LB group at 24, 48, and 72 hours (all p < 0.017).
- No significant differences were found in AUC-rNRS among the groups (p > 0.05).
- Postoperative recovery and adverse events showed no significant differences (p > 0.05).
Why it matters
Understanding the efficacy of different analgesic techniques is crucial for optimizing postoperative pain management. This study suggests that while high-dose liposomal bupivacaine may offer some benefits, it does not outperform ropivacaine, indicating the need for further research to enhance analgesic strategies.